The drug development for AD is characterized by continuous failures to show clinical effects and improvement of cognitive function since more than 10 years. Enormous financial and research effort has put into the development of new compounds and in spite of sometimes encouraging data from Phase II clinical testing, the final proof of efficacy failed. Have the wrong compounds been selected for the clinical development? – Most likely, yes!
A reason could be the use of wrong instruments to investigate cognitive effects in early trials. Almost all new substances underwent intensive animal testing in the most widely used cognitive paradigm, the Morris water maze, assessing spatial orientation. How to translate these findings in to human application?
Our experts have more than 50 years’ experience of Alzheimer’s disease and other cognitive disorder clinical drug trials, gained at all stages of development.
We can assist your drug development program with:
- The direct way for drug development for cognitive disorders: from laboratory research to clinical validation
- Cognitive testing and training of raters
- Data analysis and Interpretation